First Quadrant L P CA Raises Holdings in Illumina, Inc. (ILMN)

Share on StockTwits

First Quadrant L P CA raised its position in Illumina, Inc. (NASDAQ:ILMN) by 59.0% during the third quarter, HoldingsChannel reports. The institutional investor owned 636 shares of the life sciences company’s stock after purchasing an additional 236 shares during the period. First Quadrant L P CA’s holdings in Illumina were worth $233,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Jennison Associates LLC grew its holdings in Illumina by 4.5% in the 2nd quarter. Jennison Associates LLC now owns 4,297,581 shares of the life sciences company’s stock valued at $1,200,271,000 after buying an additional 185,745 shares in the last quarter. Fred Alger Management Inc. grew its holdings in Illumina by 21.4% in the 2nd quarter. Fred Alger Management Inc. now owns 778,450 shares of the life sciences company’s stock valued at $217,413,000 after buying an additional 137,302 shares in the last quarter. Schwab Charles Investment Management Inc. grew its holdings in Illumina by 5.6% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 604,615 shares of the life sciences company’s stock valued at $168,863,000 after buying an additional 31,985 shares in the last quarter. Millennium Management LLC grew its holdings in Illumina by 219.8% in the 2nd quarter. Millennium Management LLC now owns 548,957 shares of the life sciences company’s stock valued at $153,318,000 after buying an additional 377,283 shares in the last quarter. Finally, Federated Investors Inc. PA grew its holdings in Illumina by 4.1% in the 2nd quarter. Federated Investors Inc. PA now owns 512,611 shares of the life sciences company’s stock valued at $143,167,000 after buying an additional 20,324 shares in the last quarter. 89.87% of the stock is currently owned by hedge funds and other institutional investors.

NASDAQ:ILMN opened at $303.75 on Wednesday. The firm has a market cap of $43.38 billion, a PE ratio of 75.94, a P/E/G ratio of 2.19 and a beta of 0.97. The company has a quick ratio of 2.24, a current ratio of 2.46 and a debt-to-equity ratio of 0.24. Illumina, Inc. has a fifty-two week low of $203.39 and a fifty-two week high of $372.61.

Illumina (NASDAQ:ILMN) last released its earnings results on Tuesday, October 23rd. The life sciences company reported $1.52 earnings per share for the quarter, beating analysts’ consensus estimates of $1.26 by $0.26. The firm had revenue of $853.00 million during the quarter, compared to the consensus estimate of $825.65 million. Illumina had a return on equity of 27.10% and a net margin of 21.09%. The company’s revenue was up 19.5% compared to the same quarter last year. During the same period in the prior year, the company posted $1.11 EPS. On average, research analysts expect that Illumina, Inc. will post 5.75 earnings per share for the current year.

In related news, Director Jay T. Flatley sold 3,300 shares of the company’s stock in a transaction on Wednesday, October 24th. The stock was sold at an average price of $310.58, for a total transaction of $1,024,914.00. Following the completion of the sale, the director now directly owns 382,304 shares in the company, valued at approximately $118,735,976.32. The sale was disclosed in a filing with the SEC, which is available through this link. Also, SVP Mostafa Ronaghi sold 10,000 shares of the company’s stock in a transaction on Friday, August 10th. The stock was sold at an average price of $331.39, for a total value of $3,313,900.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 53,183 shares of company stock valued at $17,883,841. Corporate insiders own 0.54% of the company’s stock.

A number of research analysts have commented on the company. Zacks Investment Research lowered Illumina from a “buy” rating to a “hold” rating in a report on Wednesday, October 24th. Barclays upped their price objective on Illumina from $350.00 to $370.00 and gave the company an “overweight” rating in a report on Wednesday, October 24th. BidaskClub lowered Illumina from a “buy” rating to a “hold” rating in a report on Tuesday, October 16th. Deutsche Bank upped their price objective on Illumina to $350.00 and gave the company a “buy” rating in a report on Friday, October 12th. Finally, ValuEngine lowered Illumina from a “strong-buy” rating to a “buy” rating in a report on Thursday, October 11th. Six analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $330.94.

Illumina Company Profile

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.

Featured Story: Preferred Stock

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply